Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Talks Drug Safety With China, But Visas For Staff Still Elusive

Executive Summary

Agency unable to place more inspectors in China even as Howard Sklamberg visits Beijing.

You may also be interested in...



US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security

After receiving delayed visas, additional FDA is inspectors and other staff can relocate to China office; Gottlieb also announces increase in international mail facility staff.

How FDA Plans To Stop Worrying And Love Globalization

New deputy commissioner Howard Sklamberg tells “The Pink Sheet” that globalization of the drug supply eventually will become more commonplace, and ideally less of a concern, for American consumers.

FDA Inspection Growth In China Stymied By Visa Issues

The agency is waiting for approval to locate 10 new drug inspectors in China.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel